Obstructive Jaundice — Viva Defence

Long case viva — pancreatic head cancer presenting as obstructive jaundice

Candidate's opening statement (SASPOP)

"Doctor, my patient is a 68-year-old man with four weeks of painless progressive obstructive jaundice from a pancreatic head mass. His problems are: obstructive jaundice with a bilirubin of 210 micromol per litre, pale stools and dark urine; a 7-kilogram weight loss suggesting malignancy; Courvoisier sign (palpable gallbladder) pointing to a malignant distal obstruction; a markedly elevated CA 19-9 at 420 U per mL; and a 3 cm pancreatic head mass on triple-phase CT with no vascular encasement and no metastases, classifying the tumour as resectable. My priorities are to obtain tissue confirmation by EUS-FNA, to exclude autoimmune pancreatitis with a serum IgG4, to stage definitively with possible staging laparoscopy, and to proceed to pancreaticoduodenectomy with curative intent, avoiding routine preoperative biliary drainage which has been shown to increase complications." ^[1]

Problem list

1. Obstructive (surgical) jaundice — conjugated hyperbilirubinaemia, elevated ALP and GGT, pale stools, dark urine, pruritus.
2. Pancreatic head mass — likely pancreatic ductal adenocarcinoma; resectable on CT staging.
3. Weight loss and possible new-onset diabetes — paraneoplastic or direct endocrine effect.
4. Courvoisier sign — strongly suggests malignancy over stone disease ^[5].
5. Elevated CA 19-9 — consistent with pancreatic malignancy, but limited by false positives in obstruction and false negatives in Lewis-negative individuals ^[4].

Integrated management plan

Tissue diagnosis. EUS-FNA of the pancreatic head mass to confirm adenocarcinoma before committing to surgery or neoadjuvant therapy. EUS-FNA has a sensitivity of 85 to 92 per cent and a specificity of 95 to 98 per cent for solid pancreatic lesions ^[8].

Exclude mimics. Check serum IgG4 to exclude autoimmune pancreatitis (type 1, IgG4-related), which presents as painless obstructive jaundice with a pancreatic mass and is steroid-responsive rather than surgical. ^[1]

Staging. Triple-phase CT has confirmed resectability (no vascular encasement, no metastases). Staging laparoscopy immediately before laparotomy to exclude occult peritoneal and liver metastases ^[3].

Resection. Pancreaticoduodenectomy (Whipple) with curative intent — the only potentially curative treatment for pancreatic ductal adenocarcinoma. Adjuvant chemotherapy (gemcitabine-based or FOLFIRINOX depending on fitness). ^[1]

Pre-operative optimisation. Correct the coagulopathy with vitamin K (check INR; corrects if hepatocytes are intact). Optimise nutrition and glycaemic control. Assess cardiac and respiratory fitness for major surgery. ^[1]

No routine preoperative biliary drainage. The van der Gaag NEJM 2010 trial showed routine PBD increased serious complications from 39 to 74 per cent. Reserve PBD for cholangitis, delayed surgery, or neoadjuvant therapy ^[6].

Palliative pathway if unresectable. If staging laparoscopy reveals metastases, the approach shifts to ERCP biliary stenting (self-expanding metal stent for longer patency), palliative chemotherapy, celiac plexus neurolysis for pain, and palliative care involvement. ^[1]

Examiner probing questions

Examiner: "What is Courvoisier sign and how reliable is it?" Courvoisier sign is a palpable, non-tender, distended gallbladder in a jaundiced patient. The law states that in jaundice, a palpable gallbladder is unlikely to be due to gallstones (because chronic stone disease thickens and fibroses the gallbladder wall, preventing distension) and is more likely due to malignancy (which causes slow progressive obstruction of a compliant gallbladder). Modern evidence shows it has a low sensitivity but a moderate-to-high specificity for malignancy. Its absence does not exclude malignancy, but its presence strongly suggests it ^[5].

Examiner: "Why is the bilirubin conjugated and why are the stools pale?" Obstruction of the common bile duct prevents conjugated bilirubin from reaching the gut. It refluxes back into the bloodstream (conjugated hyperbilirubinaemia) and is filtered by the kidney (dark urine). Because no bilirubin reaches the gut, stercobilin is not formed and the stools become acholic (pale, clay-coloured). The elevated ALP and GGT reflect the cholestatic injury to hepatocytes and canaliculi; the GGT confirms the hepatic origin of the ALP. ^[1]

Examiner: "What are the limitations of CA 19-9 in this patient?" CA 19-9 is falsely elevated in benign biliary obstruction, cholangitis, and cirrhosis, so it cannot distinguish malignant from benign obstruction with certainty. It is also falsely normal in the 5 to 10 per cent of the population who are Lewis-antigen-negative and cannot synthesise it. It is therefore a monitoring marker (for treatment response and recurrence) rather than a diagnostic or screening marker. The diagnosis is made by imaging and tissue ^[4].

Examiner: "Would you drain this patient's biliary tree before surgery?" No. Routine preoperative biliary drainage before pancreaticoduodenectomy is not recommended. The van der Gaag NEJM 2010 randomised trial showed that PBD was associated with a higher rate of serious complications (74 versus 39 per cent) compared with early surgery, with many complications related to the stenting procedure. I would reserve PBD for cholangitis, if surgery must be delayed, or for neoadjuvant chemotherapy. I would proceed to early surgery with coagulation corrected ^[6].